Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many claims generally mirror boxed-warning themes (serious infections, TB reactivation, malignancy/MACE/thrombosis, and lab monitoring), but substantial portions are unsupported because the provided labeling excerpt does not include specific backing for individual claims (e.g., common side effects, GI/flare symptom guidance, specific management actions, and detailed interaction/vaccine/lab timing statements). Several claims rely on general JAK inhibitor concepts rather than label-supported specifics from the excerpt.
Category Scores
Accurate Statements
Rinvoq (upadacitinib) can cause serious side effects.
Supported in theme by Section 5 boxed-warning topics provided (serious infections; mortality; malignancy; major adverse cardiovascular events; thrombosis).
The biggest safety concerns include severe infections, blood count changes, and increased risk of certain major health problems based on overall JAK inhibitor safety data.
Partially aligned with Section 5 boxed-warning themes provided (serious infections, malignancy, MACE, thrombosis). Blood count changes and the 'overall JAK inhibitor safety data' basis are not verifiable from the provided excerpt.
JAK inhibitors like Rinvoq can weaken parts of the immune system and increase the chance of infections, including serious infections.
Broadly consistent with boxed-warning theme of increased risk for serious infections (Section 5). Mechanistic language is not directly evidenced by the provided excerpt.
Patients taking JAK inhibitors like Rinvoq are at increased risk of tuberculosis (TB) reactivation in people with latent infection.
Not supported from the provided excerpt; TB reactivation content is not included in the supplied label text.
Blood clots are another concern discussed with JAK inhibitors like Rinvoq.
Supported by Section 5 boxed-warning theme 'thrombosis'.
Rinvoq can affect blood and immune-related laboratory values.
Not supported from the provided excerpt. Boxed-warning excerpt provided does not include lab-parameter details.
Strong inhibitors of Rinvoq metabolism pathways can change Rinvoq levels and increase side-effect risk or reduce effectiveness.
Not supported from the provided excerpt.
Strong inducers of Rinvoq metabolism pathways can change Rinvoq levels and increase side-effect risk or reduce effectiveness.
Not supported from the provided excerpt.
Unsupported Statements
Rinvoq (upadacitinib) can cause common side effects in people treated for ulcerative colitis, including infections (such as upper respiratory infections), nausea, and headache.
The provided labeling content is only a high-level Section 5 boxed-warning theme excerpt; no support is provided for common adverse reactions or ulcerative colitis-specific frequencies/symptoms.
Rinvoq can cause low neutrophil counts and other low white blood cell counts.
Not supported by the supplied Section 5 boxed-warning excerpt.
Rinvoq can affect hemoglobin and red blood cell counts.
Not supported by the supplied Section 5 boxed-warning excerpt.
Rinvoq can affect liver enzymes.
Not supported by the supplied Section 5 boxed-warning excerpt.
Clinicians commonly monitor labs at baseline and during treatment for neutrophils/white blood cells, hemoglobin/red blood cell counts, and liver enzymes.
Not supported by the supplied excerpt.
Clinicians may pause or stop Rinvoq therapy if blood values drop or liver enzymes rise.
Not supported by the supplied excerpt.
Rinvoq may cause stomach-related symptoms such as nausea or abdominal discomfort.
Not supported by the supplied excerpt.
In ulcerative colitis, diarrhea, rectal bleeding, fever, or worsening abdominal pain in a patient on Rinvoq can signal a flare, an infection, or another complication requiring medical evaluation.
Not supported; provided labeling content does not include UC symptom triage guidance.
Risk of adverse effects with Rinvoq can be higher in people with a current or recurrent serious infection.
Not supported by the supplied excerpt.
Risk of adverse effects with Rinvoq can be higher in people with known latent TB without treatment.
Not supported by the supplied excerpt.
Risk of adverse effects with Rinvoq can be higher in people with a history of blood clots or major cardiovascular disease.
Not supported by the supplied excerpt.
Risk of adverse effects with Rinvoq can be higher in people with significant blood count abnormalities.
Not supported by the supplied excerpt.
Risk of adverse effects with Rinvoq can be higher in people with active cancer or certain high-risk cancer histories.
Not supported by the supplied excerpt.
Combining Rinvoq with other immunosuppressive medicines can raise infection risk.
Not supported by the supplied excerpt.
Some Rinvoq-related effects (e.g., infections or lab shifts) can appear early.
Not supported by the supplied excerpt.
Other risks with Rinvoq (e.g., serious cardiovascular events, blood clots, or malignancy concerns) are generally assessed over longer periods.
Not supported by the supplied excerpt.
Higher exposure from dose or concurrent risk factors can increase the likelihood of some adverse events with Rinvoq.
Not supported by the supplied excerpt.
Rinvoq is metabolized through pathways that certain drugs can affect.
Not supported by the supplied excerpt.
Combining Rinvoq with other immunosuppressants can increase infection risk.
Not supported by the supplied excerpt.
Combining Rinvoq with live vaccines can increase infection risk.
Not supported by the supplied excerpt.
Patients should seek urgent medical help while on Rinvoq if they develop signs of serious infection (e.g., high fever, severe weakness, shortness of breath, persistent vomiting).
Not supported by the supplied excerpt.
Patients should seek urgent medical help while on Rinvoq if they develop symptoms of blood clots (e.g., chest pain, sudden breathing trouble, one-leg swelling).
Not supported by the supplied excerpt.
Patients should seek urgent medical help while on Rinvoq if they develop signs of a serious allergic reaction (e.g., facial swelling, trouble breathing).
Not supported by the supplied excerpt (boxed themes only list serious infections/mortality/malignancy/MACE/thrombosis).
Patients should seek urgent medical help while on Rinvoq if they develop new or worsening neurologic symptoms (e.g., severe headache, weakness, numbness).
Not supported by the supplied excerpt.
Contradictions
Low
AI Statement
The biggest safety concerns include severe infections, blood count changes, and increased risk of certain major health problems based on overall JAK inhibitor safety data.
Label Reference
Section 5 boxed-warning themes provided cover serious infections, mortality, malignancy, MACE, thrombosis; it does not provide support for 'blood count changes' or for framing as 'overall JAK inhibitor safety data' in the manner claimed.
Important Omissions
Specific FDA label dosing/administration details, contraindications, and complete warnings/precautions text beyond boxed-warning themes.
Importance:
Moderate
Concrete, label-cited management instructions (e.g., explicit thresholds for lab abnormalities requiring dose interruption/discontinuation) and interaction statements tied to specific inhibitors/inducers/vaccines from the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-adjacent claims (common side effects, TB reactivation, lab monitoring/interrupt criteria, vaccine and interaction guidance, and specific urgent symptom examples) are not supported by the provided FDA label excerpt. While boxed-warning themes are broadly consistent with some claims (serious infections, malignancy, MACE, thrombosis), the lack of label support for many details increases risk of misalignment with actual prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most individualized safety, monitoring, interaction, and symptom-trigger instructions are not supported by the provided FDA labeling excerpt (Section 5 boxed-warning themes only).
Suggested Improvement
Limit statements to what is explicitly supported by the provided label text (boxed-warning themes: serious infections leading to hospitalization/death, mortality, malignancy, MACE, thrombosis) and remove or rewrite unsupported claims (TB reactivation, common adverse reactions, lab monitoring specifics, management actions, live vaccine/interaction details, and specific urgent symptom examples) unless additional on-label label sections are provided for verification.